Evaluating the Efficacy and Safety of Transitioning Patients from Natalizumab to Ocrelizumab (OCTAVE)

Authors

• Kyle E Smoot, Providence Multiple Sclerosis Center, Providence Brain & Spine Institute, Portland, Oregon​Follow
• Kiren Kresa-Reahl
• P Repovic, Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington​Follow
• Jessica Craddock, Providence Multiple Sclerosis Center, Providence Sacred Heart Medical Center, Spokane, Washington​Follow
• Chiayi Chen, Providence Multiple Sclerosis Center, Providence Brain & Spine Institute, Portland, OregonFollow
• Lindsay Lucas, Providence Multiple Sclerosis Center, Providence Brain & Spine Institute, Portland, OregonFollow
• Tiffany Gervasi-Follmar, Providence Multiple Sclerosis Center, Providence Brain & Spine Institute, Portland, OregonFollow
• Stanley Cohan, Providence Multiple Sclerosis Center, Providence Brain & Spine Institute, Portland, OregonFollow

Document Type

Article

Publication Date

2019

Keywords

oregon; providence neuroscience institute

Area of Special Interest

Neurosciences (Brain & Spine)

Specialty/Research Institute

Neurosciences